How Polivy Proved Effective in Key Clinical Trials
Polivy (polatuzumab vedotin-piiq), an antibody-drug conjugate from Genentech, gained FDA approval for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) based on the phase 2 GO29365 trial. This open-label study randomized 80 patients to receive Polivy plus bendamustine and rituximab (Pola-BR) versus BR alone. The primary endpoint was objective response rate (ORR), with Polivy-BR showing 40% ORR (complete response in 18%) compared to 18% for BR (complete response in 0%). Median duration of response was 12.4 months versus 4.7 months, and median progression-free survival (PFS) reached 9.5 months versus 3.7 months.[1][2]
Approval hinged on these superior response metrics, confirmed by independent review committees using Lugano criteria for lymphoma assessment. Progression-free survival data, adjusted for imbalances like age and refractory status, supported the benefit despite the trial's smaller size.[3]
What Made the GO29365 Trial Design Rigorous Enough for Approval?
The trial used randomization (1:1) and stratification by factors like refractory disease and prior transplant to minimize bias. Patients had received at least one prior CD20-targeted therapy, mirroring the target population. Crossover wasn't allowed, preserving intent-to-treat analysis. FDA granted accelerated approval in June 2019, later converting to full approval in 2023 after confirmatory data.[1][4]
Independent radiology and oncology reviews reduced subjectivity, with sensitivity analyses confirming PFS hazard ratio of 0.73 (95% CI 0.47-1.13), favoring Polivy despite not reaching statistical significance for all subgroups.[3]
Confirmatory Trials: Phase 3 POLARIX and Beyond
The phase 3 POLARIX trial (n=880) confirmed benefits in first-line DLBCL, randomizing Polivy-R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) against R-CHP standard. At median 28-month follow-up, Polivy met the primary PFS endpoint with 27.3% risk reduction (HR 0.73, 95% CI 0.57-0.95; p=0.009). Two-year PFS was 76.7% versus 70.4%, with consistent ORR (87.5% vs 88.4%). Event-free survival also improved (HR 0.72).[5][6]
Ongoing trials like POLARGO (vs. R-GemOx in relapsed settings) explore further indications, but POLARIX solidified Polivy's frontline role, leading to 2023 label expansion.[7]
How Do Endpoints Translate to Real-World Effectiveness?
Trials measure ORR, complete response rates, PFS, and overall survival via RECIL criteria, focusing on tumor shrinkage and time to progression. Polivy's mechanism—targeting CD79b to deliver monomethyl auristatin E payload—showed higher complete responses, correlating with longer remissions. However, overall survival benefits remain immature (HR 0.86 in POLARIX, not significant yet).[5]
Challenges include toxicity (e.g., neutropenia in 42% of Polivy-BR patients vs. 24% BR), addressed via dose adjustments.[2] Real-world data from studies like those in the Flatiron database align with trial PFS gains.[8]
When Do Patents Expire for Polivy?
Polivy's key U.S. composition-of-matter patent (US 8,153,768) expires in 2028, with formulation patents extending to 2032. Pediatric exclusivity adds six months. No major challenges reported yet on DrugPatentWatch.com.[9]
[1]: FDA Label for Polivy (2023) - fda.gov
[2]: Sehn et al., Lancet Oncology (2019) - thelancet.com
[3]: FDA Review Summary (2019) - fda.gov
[4]: FDA Approval Announcement (2023) - fda.gov
[5]: Tilly et al., NEJM (2022) - nejm.org
[6]: ESMO 2023 Update - esmo.org
[7]: ClinicalTrials.gov (POLARGO, NCT04182204) - clinicaltrials.gov
[8]: Olszewski et al., Blood Advances (2023) - ashpublications.org
[9]: DrugPatentWatch.com - Polivy Patents - drugpatentwatch.com